Dr. Carlos Ramos, MD
Claim this profileHouston Methodist Hospital
Studies Lymphoma
Studies Non-Hodgkin's Lymphoma
12 reported clinical trials
16 drugs studied
Area of expertise
1Lymphoma
CD30 positive
CD19 positive
CD19CAR positive
2Non-Hodgkin's Lymphoma
CD19 positive
CD19CAR positive
CD30 positive
Affiliated Hospitals
Clinical Trials Carlos Ramos, MD is currently running
CAR T-cell Therapy
for Lymphoma
This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK/TL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma). Patients lymphoma has come back or not gone away after treatment. Because there is no standard treatment for the patients cancer at this time or because the currently used treatments do not work fully in all cases, the patients are being asked to volunteer in this research study. In this study the investigators want to test a type of T cell made from a normal donor. The T cells the investigators will use are called Epstein Barr virus (EBV) specific T cells (EBVSTs) and are cells that the investigators have trained in the laboratory to recognize a EBV which is the virus that causes mono or kissing disease. Some patients with lymphoma have EBV in their cancer cells. Researchers have given T cell lines from normal donor EBVSTs to lymphoma patients who have EBV in their lymphoma cells and have seen responses in about half the patients. The cells have have been generated and are frozen in a bank. The cells are called "allogeneic" (meaning the donor is not related to the patient). CD30.CAR in EBV-specific T cells (called allogeneic CD30.CAR-EBVST) from the blood of healthy donors. The investigators are giving the cells to patients with lymphoma cells that express CD30. If the lymphoma cells also express EBV there may be some benefit from targeting both proteins. The purpose of this study is to find out the highest safe dose of allogeneic CD30.CAR-EBVST cells given following chemotherapy and used to treat lymphoma. The investigators will learn the side effects of CD30.CAR-EBVST cells in patients and see whether this therapy may help lymphoma patients
Recruiting1 award Phase 11 criteria
CAR T Cell Therapy
for Lymphoma
The subject has a type of lymph gland cancer called Lymphoma. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected with germs. Both antibodies and T cells have been used to treat patients with cancers; they both have shown promise, but have not been strong enough to cure most patients. Investigators hope that both will work better together. Investigators have found from previous research that they can put a new gene into T cells that will make them recognize cancer cells and kill them. They now want to test whether these genetically modified T cells given after chemotherapy will be more effective at killing cancer cells. The gene that will be put into the T cells makes an antibody called anti-CD30. This antibody sticks to lymphoma cells because of a substance on the outside of the cells called CD30. Anti-CD30 antibodies have been used to treat people with lymphoma, but have not been strong enough to cure most patients. For this study, the anti-CD30 antibody has been changed so that instead of floating free in the blood it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD30 chimeric receptor-activated T cells (CD30.CAR T cells) seem to kill some of the tumor, but they don't last very long and so their chances of fighting the cancer are unknown. Several studies suggest that the infused T cells need room to be able to multiply and grow to accomplish their functions, and that this may not happen if there are too many other T cells in circulation. Because of that, doctors may use chemotherapy drugs to decrease the level of circulating T cells prior to the CD30.CAR T cells infusion. This is called "lymphodepletion" CD30.CAR T cells have previously been studied in lymphoma patients.
Recruiting1 award Phase 1
More about Carlos Ramos, MD
Clinical Trial Related2 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Carlos Ramos, MD has experience with
- Fludarabine
- Cyclophosphamide
- Nivolumab
- CD19.CAR-aNKT Cells
- CD19.CAR-CD28Z T Cells
- CD19CAR/virus Specific T Cells
Breakdown of trials Carlos Ramos, MD has run
Lymphoma
Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
T-Lymphoblastic Leukemia/Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Carlos Ramos, MD specialize in?
Carlos Ramos, MD focuses on Lymphoma and Non-Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved CD30 positive patients, or patients who are CD19 positive.
Is Carlos Ramos, MD currently recruiting for clinical trials?
Yes, Carlos Ramos, MD is currently recruiting for 4 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Carlos Ramos, MD has studied deeply?
Yes, Carlos Ramos, MD has studied treatments such as Fludarabine, Cyclophosphamide, Nivolumab.
What is the best way to schedule an appointment with Carlos Ramos, MD?
Apply for one of the trials that Carlos Ramos, MD is conducting.
What is the office address of Carlos Ramos, MD?
The office of Carlos Ramos, MD is located at: Houston Methodist Hospital, Houston, Texas 77030 United States. This is the address for their practice at the Houston Methodist Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.